Edwards Lifesciences Corp EW
We take great care to ensure that the data presented and summarized in this overview for Edwards Lifesciences Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EW
View all-
Vanguard Group Inc Valley Forge, PA70.4MShares$6.07 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY51MShares$4.4 Billion0.11% of portfolio
-
State Street Corp Boston, MA25.6MShares$2.21 Billion0.07% of portfolio
-
Jpmorgan Chase & CO New York, NY25.1MShares$2.16 Billion0.13% of portfolio
-
Wellington Management Group LLP Boston, MA20.8MShares$1.8 Billion0.3% of portfolio
-
Jennison Associates LLC14MShares$1.2 Billion0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA12.8MShares$1.11 Billion0.07% of portfolio
-
Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Frankfurt Am Main, 2M9.24MShares$797 Million0.68% of portfolio
-
Ninety One Uk LTD London, X07.91MShares$683 Million1.42% of portfolio
-
Brown Advisory Inc7.36MShares$635 Million0.8% of portfolio
Latest Institutional Activity in EW
Top Purchases
Top Sells
About EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Insider Transactions at EW
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2025
|
Heisz Leslie Stone Director |
SELL
Open market or private sale
|
Direct |
2,615
-7.79%
|
$217,045
$83.41 P/Share
|
|
Dec 12
2025
|
Daniel J. Lippis CVP, JAPAC |
SELL
Open market or private sale
|
Direct |
1,019
-4.43%
|
$85,596
$84.03 P/Share
|
|
Dec 12
2025
|
Daniel J. Lippis CVP, JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
1,019
+4.24%
|
$60,121
$59.26 P/Share
|
|
Dec 12
2025
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Bona fide gift
|
Direct |
7,100
-18.22%
|
-
|
|
Dec 12
2025
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
11,386
-12.02%
|
$945,038
$83.76 P/Share
|
|
Dec 11
2025
|
Daveen Chopra CVP, TMTT & Surgical |
SELL
Open market or private sale
|
Direct |
2,000
-5.85%
|
$168,000
$84.38 P/Share
|
|
Dec 10
2025
|
Bernard J Zovighian CEO |
SELL
Open market or private sale
|
Indirect |
3,863
-31.01%
|
$320,629
$83.45 P/Share
|
|
Dec 10
2025
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
11,340
-18.38%
|
$941,220
$83.83 P/Share
|
|
Dec 10
2025
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
11,340
+15.53%
|
$669,060
$59.26 P/Share
|
|
Dec 09
2025
|
Bernard J Zovighian CEO |
BUY
Bona fide gift
|
Indirect |
3,863
+23.67%
|
-
|
|
Dec 09
2025
|
Bernard J Zovighian CEO |
SELL
Bona fide gift
|
Direct |
3,863
-4.55%
|
-
|
|
Dec 09
2025
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,700
-16.18%
|
$646,800
$84.47 P/Share
|
|
Dec 09
2025
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,700
+13.92%
|
$454,300
$59.26 P/Share
|
|
Dec 08
2025
|
Bernard J Zovighian CEO |
SELL
Open market or private sale
|
Direct |
21,487
-20.21%
|
$1,826,395
$85.21 P/Share
|
|
Dec 08
2025
|
Bernard J Zovighian CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,350
+19.25%
|
$1,495,650
$59.26 P/Share
|
|
Dec 08
2025
|
Wayne Markowitz CVP, JAPAC |
SELL
Open market or private sale
|
Direct |
583
-3.21%
|
$50,138
$86.01 P/Share
|
|
Nov 13
2025
|
Andrew M. Dahl SVP, Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,160
+11.22%
|
-
|
|
Nov 10
2025
|
Daniel J. Lippis CVP, JAPAC |
SELL
Open market or private sale
|
Direct |
1,020
-4.43%
|
$83,640
$82.55 P/Share
|
|
Nov 10
2025
|
Daniel J. Lippis CVP, JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
1,020
+4.24%
|
$60,180
$59.26 P/Share
|
|
Nov 10
2025
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,000
-12.85%
|
$1,079,000
$83.16 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 146K shares |
|---|---|
| Exercise of conversion of derivative security | 184K shares |
| Bona fide gift | 20.4K shares |
| Open market or private sale | 226K shares |
|---|---|
| Payment of exercise price or tax liability | 22.8K shares |
| Bona fide gift | 27.5K shares |